But also AKT signalling has been implicated during mistletoe lectin or oleanolic acid treatment of gastric cancer, hepatocarcinoma, epidermoid cancer, colon carcinoma, ovarian cancer, prostate cancer, osteosarcoma and trophoblast cells, and oleanolic acid and its derivatives have been demonstrated to induce MTOR and NFKB1 signalling in prostate cancer, colon cancer and osteosarcoma cells [23, 26–34]. The gene discussed is AKT1; the disease is prostate carcinoma.